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Abstract
Adeno-associated virus (AAV) has become a leading gene transfer vector for striated muscles. 
However, the AAV vectors also exhibit broad tropisms after systemic delivery. In an attempt to 
improve muscle tropism, we inserted a 7-amino-acid (ASSLNIA) muscle-targeting peptide (MTP) 
in the capsids of AAV2 at residue 587 or 588, generating AAV587MTP and AAV588MTP. In vitro 
studies showed that both viruses diminished their infectivity on non-muscle cell lines as well as on 
un-differentiated myoblasts, however, preserved or enhanced their infectivity on differentiated 
myotubes. AAV587MTP, but not AAV588MTP, also abolished its heparin-binding capacity and 
infected myotubes in a heparin-independent manner. Furthermore, in vivo studies by intravenous 
vector administration in mice showed that AAV587MTP enhanced its tropism to various muscles 
and particularly to the heart (24.3 fold of unmodified AAV2), whereas reduced its tropism to the 
non-muscle tissues such as the liver, lungs and spleen, etc. This alteration of tissue tropism is not 
simply due to the loss of heparin-binding, since a mutant AAV2 (AAVHBSMut) containing 
heparin-binding site mutations lost infectivity on both non-muscle and muscle cells. Furthermore, 
free MTP peptide, but not the scrambled control peptide, competitively inhibited AAV587MTP 
infection on myotubes. These results suggest that AAV2 could be re-targeted to the striated 
muscles by a muscle-targeting peptide inserted after residue 587 of the capsids. This proof of 
principle study showed first evidence of peptide-directed muscle targeting upon systemic 
administration of AAV vectors.
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Diseases of the heart and skeletal muscles affect adults and children worldwide. Gene 
therapy represents an attractive strategy for a variety of muscle diseases such as muscular 
dystrophies and heart failure.1,2 Gene transfer vectors, including non-viral and viral vectors, 
have been shown to accomplish gene delivery to local muscle and heart tissue by direct 
intramuscular (i.m.) injection or by local vessel perfusion.3,4 The simplest approach of gene 
therapy is the injection of naked plasmid DNA encoding the therapeutic gene into muscle.5 
Although plasmid DNA delivery could achieve long-term gene expression,6 the delivery 
efficiency of naked plasmid is low following i.m. injection. Viral vectors, especially the 
AAV vectors,7 offer effective alternative approaches for muscle-directed gene transfer. To 
functionally correct disorders affecting the heart and skeletal muscles, delivery of gene 
vectors to a majority of the diseased cells is required. Following direct i.m. injection, AAV 
vectors can readily saturate individual muscles around the injection sites.8 Gene transfer to 
large groups of muscles by multiple i.m. injections is feasible9 but ineffective and 
impractical for muscular dystrophies that affect muscles body-wide. Systemic delivery of 
AAV vectors to the muscle and heart has been achieved by a single intravenous (i.v.) or 
intraperitoneal (i.p.) of AAV vectors.10,11 However, the AAV vectors also non-specifically 
infect a variety of non-muscle tissues. As a result, targeting the AAV vectors to the muscle 
after systemic delivery is a highly desirable and yet challenging task for muscle-directed 
gene therapy.
One of the approaches of targeting AAV to the muscle is to alter its native interactions with 
the cellular receptors and retarget the virus through a different binding ligand to the muscle. 
Among the currently used AAV serotypes, AAV2 is the best characterized serotype for its 
viral-cellular interactions. It is also the best documented AAV vector in pre-clinical studies 
and clinical trials in the past 20 years.12 Therefore, AAV2 can serve as a good candidate for 
genetic engineering of detargeting and retargeting. AAV2 uses cell membrane-associated 
heparan sulfate proteoglycan (HSPG) as its primary binding receptor and its transduction 
can be efficiently competed by free heparin.13 In addition, AAV2 utilizes a number of 
membrane proteins such as αVβ5 integrin,14 fibroblast growth factor receptor-1 (FGFR1),
15 hepatocyte growth factor receptor (c-Met),16 and α5β1 integrin17 as its co-receptors for 
cell entry. As AAV tropism is determined by a specific interaction between viral capsids and 
host cellular receptors,13–17 modification of capsid proteins has emerged as a means to 
alter native vector tropism. In addition, incorporation of targeting peptides selected by either 
phage display18 or AAV display19 on the surface of AAV capsids has been used to target 
the vector to specific cell types.20–25 Previously, insertion of an angiogenic vascular 
targeting motif NGR on AAV2 capsid successfully redirected vector tropism to cells 
expressing the NGR receptor CD13 that is presented in angiogenic vasculature and in many 
tumor cell lines.22 Similarly, the incorporation of endothelium-specific peptide SIGYPLP 
into the AAV2 capsid at position 587 displayed an altered tropism toward human vascular 
endothelial cells. The infection happened to be independent of HSPG binding.23 A recent 
study also demonstrated that the insertion of MTPFPTSNEANL peptide into AAV2 capsid 
after amino acid 587 enhanced gene delivery of AAV vectors into a specific vascular site in 
vivo and these vectors transduced the vena cava independently of HSPG binding.24 
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Moreover, Work et al.25 identified peptides homing to the lung and brain by in vivo phage 
display from rats and they showed that the isolated targeting peptides retargeted AAV 
vectors to the expected organs in a preferential manner. However, no efforts have been 
reported on systemic re-targeting of AAV to the muscles, either cardiac and/or skeletal.
In this report we describe the construction and evaluation of AAV2 vectors genetically 
modified with a muscle-targeting peptide (MTP), which was originally isolated by phage 
display in differentiated muscle cells in vitro and muscle tissue in vivo.26,27 The MTP-
modified AAV2 showed improved tropisms to the striated muscles, and could efficiently 
and selectively infect differentiated muscle cells in vitro and skeletal and cardiac muscles in 
vivo.
RESULTS
Genetic Modification of AAV2 capsids with a muscle-targeting peptide (MTP)
Ligand insertion at amino acid residues 587 and 588 of AAV2 capsids can be well tolerated.
19,22–25 We therefore genetically inserted the muscle-targeting peptide ASSLNIA26,27 
after 587 or 588 site of the AAV2 capsid gene, resulting two MTP-modified AAV2 capsid 
mutants: AAV587MTP and AAV588MTP (Fig. 1a). The MTP insertion after 587 of the 
AAV2 capsid disrupted the heparin-binding motif and is expected to lose its heparin-binding 
capability, which is the primary mechanism of AAV2 cell binding and entry.13 In addition, 
we have generated a third mutant: AAVHBSMut, which had all three arginines mutated 
(R484E, R585A and R588A) at the heparin-binding site of the AAV2 capsids (Fig. 1a). But 
further insertion of MTP after 587 of AAVHBSMut caused failure of AAV vector 
packaging (data not shown). The above three mutant AAV capsids were used to package 
AAV vectors containing either GFP or luciferase reporter genes. DNA dot-blot assays 
showed that all three mutant AAVs could yield AAV vector titers comparable to that of the 
unmodified AAV2 (data not shown). Furthermore, Western analysis using the same quantity 
of viral particles (viral genomes v.g.) of the three mutants and the unmodified AAV2 did not 
reveal abnormal quantity or stoichiometry of capsid proteins, VP1, VP2 and VP3 (Fig. 1b), 
suggesting that the formation of the viral particles and the DNA packaging capacity were 
not impaired by these mutations.
MTP re-targets AAV2 to myotubes and abolishes infectivity to non-muscle cells in vitro
We next examined the effects of MTP insertion on the infectivity of AAV2 in vitro on 
differentiated muscle cells, the myotubes. Since the ASSLNIA peptide was originally 
isolated by phage-display selection in murine C2C12 myotubes26 that express many of the 
proteins presented in skeletal muscles, C2C12 myotubes were used to validate the muscle-
targeting efficiencies of peptide-modified AAV vectors in vitro. First, a luciferase (Luc) 
reporter vector packaged respectively by AAV587MTP, AAV588MTP, AAVHBSMut and 
unmodified AAV2 was used to infect differentiated C2C12 cells, which formed myotubes 
after differentiation. As shown in Fig. 2a, both AAV587MTP and AAV588MTP were able to 
transduce C2C12 myotubes at similar levels as the unmodified AAV2 vector, although 
AAV587MTP was slightly lower and AAV588MTP was slightly higher (Fig. 2a). As 
expected, AAVHBSMut with triple mutations on the heparin-binding site dramatically 
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abolished its transduction on C2C12 myotubes by more than 2600 fold (Fig. 2a). To confirm 
the results obtained by the luciferase reporter vectors, we also used a GFP reporter vector 
packaged in the same viral capsids and tested again on differentiated C2C12 myotubes in a 
similar fashion. Fluorescent microscopy showed green fluorescence on myotubes infected 
with unmodified AAV2, AAV587MTP and AAV588MTP but not on myotubes infected with 
AAVHBSMut (Fig. 2b), consistent with the results from the luciferase reporter vectors.
To further evaluate the targeting specificity of peptide-modified vectors, undifferentiated 
C2C12 myoblasts were infected for 2 days with the luciferase vectors. AAV587MTP and 
AAV588MTP showed decreased transduction by 92.59% and 96.95% when compared to the 
unmodified AAV2, while AAVHBSMut had almost undetectable transduction in 
undifferentiated C2C12 cells (Table 1). Similar experiments were also done using non-
muscle cell lines including HepG2, a human hepatocellular carcinoma cell line, HeLa, a 
human cervix epitheloid carcinoma cell line, HEK 293, a human embryonic kidney cell line 
and U-87MG, a human glioblastoma tumor cell line (Table 1). All three mutant AAVs 
showed dramatic decreases in transduction when compared to the unmodified AAV2, 
indicating that insertion of MTP could diminish the native infectivity of AAV2 on the 
permissive non-muscle cells in vitro.
AAV587MTP infection in myotubes is heparin-independent and MTP dependent
To examine if the insertion of MTP peptide impaired heparin-binding capacity of the mutant 
AAVs, we performed an in vitro heparin-binding assay. Three mutant AAV vectors and the 
unmodified AAV2 vector were loaded (5×1011 v.g. each) onto heparin columns for binding. 
After extensive wash, the bound AAVs were eluted by 1 M NaCl. Fractions from loading 
flow through, wash and elution were all collected for viral particle analyses. Viruses were 
monitored by DNA-dot blot using the CMV promoter probe (Fig. 3a) and also by Western 
blot using a guinea pig anti-AAV2 serum (Fig. 3b). As expected, the unmodified AAV2 
showed high affinity for the heparin column, and were only found in the elution fraction 
(Fig. 3a). AAV588MTP also displayed similar heparin-binding ability to the unmodified 
AAV2. The majority of the AAV588MTP was found in the elution fraction with negligible 
amount in the wash fraction. In contrast, AAV587MTP viruses were substantially detected in 
the wash fraction as well as in the elution faction. As expected, AAVHBSMut was detected 
in the loading flow-through faction, and mostly in the wash fraction, but undetectable in the 
elution fraction. These results suggest that the loss of heparin-binding capacities is extensive 
for AAVHBSMut, substantial for AAV587MTP but minor for AAV588MTP.
Next we performed a competitive inhibition experiment with soluble heparin to see if the 
loss of heparin binding makes the viral infection in an HSPG-independent manner. 
Differentiated C2C12 myotubes were infected with unmodified AAV2, AAV587MTP and 
AAV588MTP containing a luciferase report gene in the presence of soluble heparin, which is 
known to competitively inhibit AAV2 infection.13 As expected, the transduction of 
AAV587MTP vector was not inhibited by heparin, whereas both unmodified AAV2 and 
AAV588MTP vectors significantly diminished their transduction efficiency by 72.03% and 
42.25%, respectively, in the presence of heparin sulfate (P<0.05) (Fig. 3c).
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Finally we examined if infection of differentiated myotubes by AAV587MTP is mediated by 
the MTP peptide insertion on the capsids. Unmodified AAV2 and AAV587MTP were 
compared for their transduction efficiencies (luciferase reporter gene transfer) on C2C12 
myotubes in the presence of the specific peptide (ASSLNIA), or a scrambled peptide 
(LISNSAA). Infection without any competing peptide was used as a positive control. As 
shown in Fig. 3d, AAV587MTP transduction was significantly inhibited (47.30%) by 2 
mg/ml free ASSLNIA peptide (P<0.05), but not by free LISNSAA. The inhibition of 
unmodified AAV2 by free ASSLNIA peptide was statistically insignificant when compared 
to the control without peptide (P>0.3). These results suggest that the MTP could re-target 
AAV2 to differentiated myotubes.
MTP peptide enhances AAV588MTP infectivity to skeletal muscle after local i.m. injection
We next investigated if the MTP could enhance AAV2 infectivity to the skeletal muscles. 
Adult male ICR mice (2 months of age, 4 mice in each group) were injected in the tibialis 
anterior (TA) muscle of the hind legs with lucifierase vectors respectively packaged in 
unmodified AAV, AAV587MTP and AAV588MTP (2.5 × 1010 v.g. each). The TA muscles 
were collected at 4 weeks after i.m. injection of the vectors for luciferase activity assay. 
When compared to the control AAV2, AAV587MTP had a slightly lower luciferase gene 
expression while AAV588MTP had a 3.2 fold increase (Fig. 4). This result mirrors the 
luciferase activity profile obtained in the in vitro assay on differentiated myotubes (Fig. 2), 
suggesting that AAV587MTP might primarily use the MTP for cell entry, whereas 
AAV588MTP might use a dual mechanism, both heparin binding and MTP.
MTP peptide retargets AAV587MTP to heart and muscle after systemic i.v. injection
We next investigated if MTP could enhance the infectivity of AAV2 in vivo to the heart and 
skeletal muscles after systemic delivery by intravenous injection. Eight-week-old adult ICR 
mice were administered with unmodified AAV2, AAV587MTP, or AAV588MTP containing 
the CMV-Luciferase reporter gene cassette via the tail vein at a dose of 9 x 1011 v.g each. 
Four weeks after i.v. injection, luciferase reporter gene expression was analyzed in various 
tissues. AAV587MTP achieved higher luciferase gene expression than the unmodified 
AAV2, and surprisingly, AAV588MTP in various muscles and heart after systemic delivery. 
The luciferase activity of AAV587MTP in the heart was 24.3 fold of that of the unmodified 
AAV2, while the activity of AAV588MTP was only 1.82 fold of the unmodified AAV2 (Fig. 
5a). In skeletal muscles, the luciferase activity of AAV587MTP was 2.18-fold of the AAV2 
in the diaphragm and 2.85-fold in quadriceps (Fig. 5b). Moreover, the AAV587MTP showed 
reduced transduction in the liver, lungs, spleen, etc than the unmodified AAV2 (Fig. 5c). In 
contrast, AAV588MTP showed reduced transduction in most tissues, muscle as well as non-
muscle, after systemic delivery (Figs. 5b,c).
Quantitative PCR was also performed on samples collected from AAV2 and AAV587MTP 
treated mice for vector tissue distribution. The results showed that AAV587MTP vector 
DNA copy number in the heart increased by 6.6 fold when compared to the unmodified 
AAV2 (7.28±3.91 copies vs. 0.96±0.45 copies per μg of tissue DNA, P<0.05) (Fig. 6a). The 
vector DNA copy numbers also increased in various skeletal muscles, including diaphragm, 
upper limbs, quadriceps, gastrocnemius, and tibialis anterior muscles when compared to the 
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unmodified AAV2 vector (Fig. 6a). However, the vector DNA copy numbers of 
AAV587MTP in the liver was less than half (39.4%) of that of unmodified AAV2 (Fig. 6b). 
In addition, AAV587MTP also showed an approximately 10-fold lower vector DNA 
distribution in the lung and spleen (Fig. 6b). The real-time PCR results were essentially 
consistent with the luciferase gene expression profiles, suggesting that MTP could de-target 
AAV587MTP from non-muscle tissues and re-target it to the striated muscles including the 
heart and skeletal muscle after systemic delivery.
DISCUSSION
A number of AAV serotype vectors are able to achieve systemic gene delivery into the heart 
and skeletal muscles, but also show strong tropisms to non-muscle tissues.10,11,28,29 
Ideally, systemic delivery of therapeutic genes to striated muscles requires not only 
efficiency but also tissue specificity. In an attempt to improve the muscle tropism of AAV 
vectors by ligand-directed gene delivery, we have genetically modified AAV2 capsid 
surface with a muscle-targeting peptide, MTP, a small 7-mer peptide ASSLNIA 26,27. On 
cultured cells in vitro, the insertion of MTP not only furnished AAV2 with infectivity to 
differentiated myotubes but also ablated or impaired its infectivity to the otherwise 
permissive non-muscle cells. Furthermore, insertion of MTP at capsid position 588 was able 
to enhance AAV2 infectivity in vivo to the muscle myofibers by 3.2 fold after intramuscular 
injection. On the otherhand, MTP at position 587 could re-target AAV2 to the heart (an 
increase of 23.3 fold), and at a less degree, to skeletal muscles after systemic injection. The 
above phenomena suggest that AAV587MTP may have improved capacity to cross the 
capillary blood vessel barrier in striated muscles, particularly in the heart. Although much 
room remains for further improvement and optimization, we believe that our results 
demonstrate the first example of a ligand-directed targeting of AAV vectors to the striated 
muscle tissues. Since AAV2 is not a robust virus for either direct local or systemic gene 
delivery into the heart and muscle, the incorporation of the MTP onto the surface of capsids 
of more powerful AAV serotype capsids such as AAV7, 8 and 9, which are efficient in 
crossing the blood vessel barrier to reach muscle myofibers in vivo, could render them more 
effective in targeting muscles in vivo for systemic gene delivery.
In this study, we chose to modify serotype AAV2 with the muscle-targeting peptide, 
primarily based on the wealth of information on AAV2 viral capsid structure and functional 
relationship. Although AAV2 is not the best vector for gene delivery to the muscle, it has 
been extensively used in mutagenesis studies including point mutations, linker insertions 
and peptide display on its capsids.19–25,30 Peptide insertions at amino acid residues 587 
and 588 are well tolerated because the loop structure is exposed on the surface of the 
capsids.19,22–25,30 Insertion at 587 also interferes and abolishes viral particle binding to 
heparan proteoglycans, which are ubiquitous on cell surface of almost all tissues31 as a 
primary receptor for AAV2 attachment and cell entry.13 Ablation of heparin binding should 
facilitate tissue-specific targeting. Although both AAV587MTP and AAV588MTP had the 
same MTP insertion, AAV587MTP largely lost its heparin-binding capacity whereas 
AAV588MTP had a minor loss. As such, AAV587MTP exhibited better muscle-targeting in 
vivo after systemic delivery, while AAV588MTP might use a dual mechanism via both 
heparin and MTP for cell binding and entry. Importantly, the loss of heparin binding alone 
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could not account for the improved muscle-targeting of AAV587MTP, because a heparin-
binding deficient mutant AAV2 (AAVHBSMut, R484→E, R585→A and R588→A) not 
only failed to achieve significant infection on cultured myotubes (Fig. 2) but also failed to 
achieve luciferase reporter gene expression higher than basal levels in all the organs and 
tissues tested after systemic tail vein injection (data not shown). Furthermore, free MTP 
peptide, but not the scrambled peptide, on myotube culture could inhibit the transduction of 
AAV587MTP but not the unmodified AAV2, suggesting that the MTP is responsible in part 
for retargeting the AAV2 to the striated muscle tissues, particularly the heart.
In this study, we have examined two MTP-modified AAV2 capsids on cultured cells in vitro 
and in mice in vivo by direct vector injection. In the in vitro experiments, both AAV587MTP 
and AAV588MTP dramatically lost their infectivities (~ 100 fold) to all the cell types tested 
including the undifferentiated myoblast C2C12, except the differentiated muscle cells 
(myotubes). It suggested that the MTP insertion played a major role in de-targeting AAV2 
from non-muscle cells and re-targeting it to myotubes in vitro. However, the in vivo de-
targeting and re-targeting results by the MTP-modified AAV2 were much less impressive 
than the results obtained in vitro. These discrepancies could be attributed primarily to the 
profound in vitro and in vivo differences in the environment throughout the process of AAV 
infection. It is well documented that AAV2 vectors are robust in vitro but less efficient in 
vivo, while numerous new AAV serotypes are exactly the opposite. The viruses might favor 
different receptors or co-receptors in vivo. Furthermore, the serum proteins and a barrage of 
different cell types in vivo could also alter the behavior of the vectors. Another reason could 
be the high complexity and variability of in vivo experiments. In our study, reporter gene 
expression in some muscle groups showed statistic differences between the wt AAV2 and 
MTP-modified AAV2, while other groups did not. We have also observed discrepancies 
between reporter gene expression and vector DNA copy numbers in some tissues, which 
again could reflect the complex situations in vivo. For example, it was demonstrated that 
AAV2 and AAV8 had similar vector copy numbers in the liver shortly after intravenous 
vector delivery. However, AAV8 achieved dramatically high levels of gene expression due 
to more efficient intracellular trafficking and uncoating of the viral particles41. Therefore, 
direct in vivo screening and evaluation of new vectors should be a more reliable and 
preferred method.
Finally, we believe that minor differences on MTP insertion sites (587 vs. 588) and the 
linker sequences flanking the MTP made a significant difference on the behavior between 
AAV587MTP and AAV588MTP. These differences could not be simply explained by the 
alteration of heparin binding. It is conceivable to see a near complete loss of infectivity of 
AAV587MTP on the permissive non-muscle cell lines for AAV2 because of the loss of 
heparin binding. But AAV588MTP also showed a near complete loss of infectivity on those 
cells, although its heparin- binding motif RXXR (X is any amino acid) is still intact 32. 
Again unexpectedly, AAV588MTP was significantly more resistant than AAV587MTP to 
anti-AAV2 antibody neutralization using anti-sera from guinea pig, mouse and pooled 
human IVIG (data not shown), despite the presence of intact heparin-binding motif. A 
previous report showed that linker sequences flanking the peptide insertion could 
significantly influence the configuration and display of the engineered peptide epitope.33 
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Insertion of an integrin-specific peptide ligand (L14) at residue 587 of AAV2 capsid enabled 
the vector to escape antibody neutralization33. However, it was not true for AAV587MTP, 
which was as sensitive to human IVIG as the unmodified AAV2. Molecular 
modeling34,35,36 of the putative 3-dimensional structures of those capsids (data not shown) 
revealed that the loop containing the heparin-binding RXXR motif is missing on 
AAV587MTP, but still exists on AAV588MTP, supporting the in vitro heparin-binding and 
inhibition data (Fig. 3). On the other hand, the MTP loop is extended and protruding on 
AAV587MTP but takes a fold-back configuration on AAV588MTP. This may make the MTP 
on AAV588MTP less effective for muscle targeting, but more effective on stereotactic 
blockade of neutralizing antibody binding to key components on AAV2. Thus, different 
linker contexts could assign different properties on the displayed peptide. It also echoes a 
previous study that showed that the choices of linker sequences could make a big difference 
on AAV2 targeting and resistance to neutralizing antibodies 30, a very important issue for in 
vivo gene delivery with AAV vectors in human patients 37, 38.
MATERIALS AND METHODS
Cell culture
C2C12 murine myoblasts (American Type Culture Collection, Rockville, Maryland), human 
hepatocellular carcinoma HepG2 cells, human cervical carcinoma HeLa cells, human 
embryonic kidney 293 cells (HEK 293 cells), and human glioblastoma tumor U-87MG cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS). To induce the differentiation of C2C12 myoblasts into myotubes, the cells 
were switched from growth medium (DMEM with 10% FBS) to differentiation medium 
(DMEM with 2% horse serum) and were incubated in differentiation medium for up to 9 
days. After 4 days of differentiation, the C2C12 myotubes were fully formed.
Plasmid construction
The plasmid pBSKS-AAV2Cap containing AAV2 cap gene was used as the template for the 
construction of all modified capsids by using PCR. The mutations of heparin-binding sites 
on AAV2 capsid were introduced by the mutagenic primers which contain the desired 
mutation. For the peptide-modified capsids, we designed the primers encoding amino acids 
ASSLNIA flanked by peptide linker. This muscle-specific peptide (ASSLNIA) was then 
inserted into the site after residue 587/or 588 of AAV2 capsid by PCR. The synthesized 
PCR products were digested with DpnI endonuclease to eliminate the parental plasmid 
template and further added phosphates at 5′ of oligonucleotides by T4 polynucleotide kinase 
(New England BioLabs) to allow subsequent ligation. The sequences of primers are the 
following: R484E+, 5′AGC AGC AGC GAG TAT CAA AG 3′; R484E−, 5′CGT AAC 
AGG GTC AGG AAG C 3′; R585A−, 5′TGC CTG GAG GTT GGT AGA TAC AGA ACC 
AT 3′; R588A+, 5′GGC AAC GCA CAA GCA GCT ACC GCA GAT GTC 3′; 587 TG 
MTP+, 5′AAC ATC GCC GGA TTA AGT AGA CAA GCA GCT ACC GCA 3′; 587 TG 
MTP−, 5′GAG GGA GGA AGC TCC TGT GTT GCC TCT CTG GAG GTT 3′; 588 HB 
MTP+, 5′AAC ATC GCC GCC GCC CAA GCA GCT ACC GCA GAT 3′; 588 HB MTP−, 
5′GAG GGA GGA GGC GCG GCG GTT GCC TCT CTG GAG GTT 3′. The modified cap 
gene was then subcloned from pBSKS-AAV2Cap to pXX239 by EcoRV and XcmI.
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AAV vector production and evaluation of AAV titers
To produce AAV virus, the three-plasmid cotransfection method was applied.40 The 
plasmids used in transfection were the following: i) AAV-CMV-Luc plasmid with the 
luciferase (Luc) gene driven by the CMV promoter, or AAV-CB-EGFP plasmid with the 
enhanced green fluorescent protein (EGFP) gene controlled by the CB promoter (CMV 
enhancer/chicken beta-actin promoter). Both plasmids carry the promoter-driven transgene 
flanked by AAV ITRs; ii) the pXX6 plasmid, which contains the helper genes from 
adenovirus; iii) the modified pXX2 plasmid, which supplies AAV2 rep protein and modified 
capsid protein. As a control, wild-type AAV capsid was also prepared with unmodified 
pXX2 plasmid. The vector production and purification were performed according to 
previously published method with two rounds of CsCl centrifugation.40 AAV genomic titers 
were determined by DNA dot-blot assay. Briefly, 2 μl of the purified AAV stock was 
digested with DNase I (10 μg/ml) in DMEM at 37°C for one hour and then 200 μl of 2x 
proteinase K buffer (20 mM Tris.Cl pH 8.0, 20 mM EDTA pH 8.0, 1% SDS) was added. 
Next, proteinase K was added to reactions at a final concentration of 1 mg/ml and the 
samples were incubated at 55°C for one hour. Viral DNA was precipitated by ethanol and 
the DNA pellet was dissolved in an alkaline buffer (0.4 M NaOH, 10 mM EDTA pH 8.0). 
DNA samples were applied to Nylon membranes and probed with a horseradish-peroxidase-
labeled CMV or EGFP probe. Signals were detected by the North2South® 
chemiluminescence kit (Pierce). In order to detect if these mutant virions were composed of 
three capsid proteins, 2×1010 viral particles of unmodified or modified AAV-CMV-Luc 
virus were subjected to Western blotting with anti-AAV2 capsid guinea pig sera (purchased 
from ATCC).
In vitro transduction assay
C2C12 myotubes were grown in 24-well plates and infected with AAV-CMV-Luc vectors at 
2×1010 genomic particles/per well and continued to incubate at 37°C for 6 days. Then, 
myotubes were lysed for luciferase assay. In addition, the C2C12 myotubes were transduced 
with AAV-CB-EGFP at 1×1010 genomic particles/per well. EGFP expression was observed 
under a Nikon TE-300 inverted fluorescent microscope. Images were taken at 100x 
magnification at 72 hours after infection.
For transduction in undifferentiated myoblasts and non-muscle cell lines, the cells were 
seeded in 12-well plate at the following cell densities per well: C2C12 at 2×104 ; HepG2 at 
1×105 ; HeLa at 6×104 ; HEK 293 at 3×105; and U-87MG at 3×104. One day later the cells 
were infected with various AAV-CMV-Luc vectors at 103 v.g./cell except C2C12 and 
U-87MG, which were infected at 104 v.g./cell. The cells were also co-infected with Ad5 at 5 
m.o.i. for expedited transgene expression. Two days after vector infection, luciferase activity 
assay was performed. The harvested cell pellets were washed with 1x PBS and then lysed in 
100 μl of luciferase lysis buffer (0.05% Triton X-100, 0.1 M Tris-HCl pH 7.8, 2 mM 
EDTA). The lysate was centrifuged at 12,000 rpm for 15 minutes in 4°C and 20 μl or 40 μl 
of supernatant was measured for light activity using the luciferase kit (Promega) with a 
luminometer. Protein content in each sample was determined by Bradford protein assay 
(BioRad). Luciferase activities were expressed as relative light units per milligram of protein 
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(RLU/mg protein). AAV-mediated in vitro transduction assays were repeated independently 
at least two or three times in triplicate.
Determination of AAV heparin binding
In heparin column chromatography, 5×1011 genomic particles of AAV-CMV-Luc were 
suspended in 0.5 ml of viral suspension buffer (50 mM NaH2PO4, 2 mM MgCl, 2.5 mM 
KCl, 50 mM Hepes, 150 mM NaCl, pH 8.0) and were then loaded onto a 1-ml HiTrap 
heparin column (Amersham Bioscience) preequilibrated with 0.15 M NaCl and 50 mM Tris 
at pH 7.5. The column was further washed twice with 5 ml of binding buffer (10 mM 
NaH2PO4 pH 7.0) and eluted twice with 5 ml of elution buffer (10 mM NaH2PO4, 1 M NaCl 
pH 7.0). The flow-through, wash, and elution fractions were collected. 20 μl of each fraction 
was analyzed by DNA dot-blot assay with a CMV probe and was also subjected to Western 
blotting with guinea pig anti-AAV2 capsid sera. Heparin dependence was verified by 
estimating viruses present in wash or elution fraction. For in vitro heparin competition assay, 
a total of 2×1010 genomic particles of AAV-CMV-Luc vectors were first incubated with or 
without 30 μg/ml heparin (from porcine intestinal mucosa; Sigma) in DMEM containing 2% 
HS for 1 h at 37°C. AAV alone or AAV-heparin mixture was added into C2C12 myotubes 
for 72 hours. Cell were next given fresh DMEM with 2% HS and were subsequently 
incubated at 37°C for 6 days. The infected myotubes were then harvested for the luciferase 
assay. The competitive blocking experiment by the synthetic peptides was carried out on 
C2C12 myotubes. AAV-CMV-Luc and C2C12 myotubes were preincubated with 2 mg/ml 
of the synthetic muscle-specific peptide (NH2-ASSLNIA-CONH2) or the scrambled peptide 
(NH2-LISNSAA-CONH2) as control at 37°C for an hour. Then, AAV vectors were added 
onto C2C12 myotubes for 24 hours. C2C12 myotubes were washed and changed with fresh 
DMEM containing 2% HS. After 96 hours of continuous incubation, the cells were 
harvested and analyzed by luciferase assay.
Vector biodistribution studies in vivo
Eight-week-old adult male ICR-CD1 mice (4 to 6 per group) were injected intravenously via 
tail vein with a viral solution containing 9×1011 genomic particles of AAV-CMV-Luc. After 
four weeks, the mice were sacrificed and representative organs (brain, heart, liver, skeletal 
muscles, kidney, testis, and spleen) were harvested for luciferase assay. Luciferase activity 
was expressed as relative light units (RLU) per milligram of protein. Genomic DNA was 
extracted from organs using DNeasy kit (Qiagen Inc). Relative numbers of vector genome 
were determined using real-time PCR. A luciferase DNA standard curve was generated from 
serial dilutions of the pAAV CMV-Luc plasmid by use of SYBR green with 100 pmol/μl 
sense 5′-GACGCCAAAAACATAAAGAAAG-3′ and antisense 5′-
AGGAACCAGGGCGTATCTCT-3′ Luc primers. 200 ng genomic DNA was used for PCR 
amplification and the PCR products were quantified using TaqMan data analysis software 
(Applied Biosystems). All data were expressed as vector copies per ng genomic DNA. The 
following PCR reaction conditions were used: denaturation, 95°C for 2 min; 40 cycles of 
amplification, 95°C for 15 sec, 60°C for 1 min.
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In vitro data were tested by unpaired Student’s t test with one- or two-tailed test. In vivo data 
were analyzed using the nonparametric Mann-Whitney U test. Data were considered 
significant when P < 0.05.
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Figure 1. Construction of AAV mutants
(a) Schematic representation of modified AAV2 capsid amino acid sequences. The peptide 
encoding ASSLNIA amino acid sequence flanked by two different linkers was inserted after 
residue 587 or 588 in the AAV2 capsid. The amino acid changes in AAVHBSMut capsid 
compared to the wild-type AAV2 are indicated. (b) Capsid protein analysis of modified AAV 
vectors by Western blotting. Similar numbers of AAV genome-containing particles (2×1010) 
were separated on 10% SDS-PAGE and analyzed by Western blotting, using anti-AAV2 
capsid guinea pig sera.
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Figure 2. Efficiency of modified AAV-mediated gene transfer to targeted C2C12 myotubes
(a) Murine C2C12 myotubes were infected with 2×1010 genomic particles/per well of AAV-
CMV-Luc vector which carries either unmodified capsid, peptide-inserted capsid, or 
heparin-binding mutated capsid in 24-well plates. After 3 days, myotubes were replaced by 
fresh DMEM containing 2% horse serum and subsequently incubated for 6 days. Luciferase 
activity was then analyzed to evaluate the transduction efficiencies of modified AAV 
vectors. Data are shown as a bar graph with mean±standard error of the mean (SEM). 
*P<0.05 vs. unmodified AAV2 vector. (b) C2C12 myotubes were next transduced with 
AAV-CB-EGFP vectors at 1×1010 genomic particles/per well in 24-well plates. EGFP 
expression driven by the CB promoter was then observed under a Nikon TE-300 inverted 
fluorescent microscope. Pictures were taken at 72 hours after infection. Fluorescent 
photography is shown in the upper panel and the morphology of C2C12 myotubes on the 
same field as the fluorescent image is displayed in the lower panel. Scale bar, 100μm.
Yu et al. Page 15













Yu et al. Page 16













Figure 3. Analysis of mutant capsid virus binding to heparin
(a,b) Heparin-affinity column analysis. 5×1011 of unmodified or peptide-inserted viruses 
were loaded onto a prepacked and equilibrated 1 ml heparin column. Viral particles 
appeared in the flow-through, wash, and elution fractions were then detected by DNA dot-
blot with CMV probe. The fractions from the heparin-affinity column analysis were also 
analyzed by Western blot using guinea pig anti-AAV2 serum. The positions of VP1, VP2, 
and VP3 are indicated. I: Input; F: Flow-through; W: Wash step; E: Elution. (c) Evaluation 
of HSPG-dependent AAV transduction in C2C12 myotubes. C2C12 myotubes were infected 
with AAV-CMV-Luc vectors carrying unmodified or peptide-inserted capsids in the absence 
or presence of 30 μg/ml heparin and analyzed for luciferase expression to examine the 
HSPG dependence of vectors. Data are shown as mean±SEM. *Indicates P<0.05 vs. 
transduction in the absence of heparin. (d) Competitive blocking experiment by synthesized 
MTP in C2C12 myotubes. C2C12 myotubes were infected with AAV-CMV-Luc vectors in 
the presence or absence of synthesized free peptides. Level of gene transduction efficiency 
of peptide-modified vectors and unmodified AAV virus were compared by evaluating 
luciferase expression. Data are mean values±SEM. *P<0.05 vs. value in the absence of 
peptide.
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Figure 4. Intramuscular delivery (i.m.) of peptide-modified AAV vectors in mice
Luciferase activities were obtained from the TA muscles of mice injected with 2.5×1010 
genomic particles of AAV-CMV-Luc vector carrying wild-type or modified capsids 4 weeks 
before examination (n=4 TA muscles for each vector tested). Data are expressed as mean
±SEM. * P<0.05 vs. unmodified AAV2 vector.
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Figure 5. In vivo AAV-mediated gene transduction after intravenous delivery
9×1011 genomic particles of AAV were delivered to 8-week old male mice via tail vein 
injection (n=5 for unmodified AAV2, n=6 for AAV587MTP, and n=5 for AAV588MTP 
vector). Luciferase reporter gene expression in major organs was analyzed one month after 
delivery. (a) Luciferase activities in cardiac muscle after systemic delivery of peptide-
modified vectors. (b) Luciferase activities in striated muscles after systemic AAV 
administration. (c) Luciferase activities in non-muscle organs after intravenous injection of 
AAV vectors. *P<0.05 vs. unmodified AAV2 vector. Results are expressed as mean±SEM.
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Figure 6. In vivo vector distribution after intravenous delivery
9×1011 viral particles of AAV were administered to 2-month old male mice via tail vein 
injection (n=5 for unmodified AAV2, and n=6 for AAV587MTP). Vector distribution was 
quantified by real-time PCR. (a) AAV genome distribution in non-muscle and muscle tissues. 
(b) Quantify hepatic AAV viral genomes after systemic delivery. Data represent means
±SEM. * P<0.05 vs. unmodified AAV2 vector.
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Table 1
Loss of infectivity on permissive cells by AAV2 after MTP-modification*
Cell lines AAV2 wt AAV587MTP AAV588MTP AAVHBSMut
C2C12 1.94×105±6.11×104 1.44×104±7.11×103 5.93×103±9.80×102 3.47×103±3.08×102
HepG2 7.83×106±1.33×106 5.92×104±2.42×104 7.31×105±1.21×105 N/D
HeLa 1.44×106±3.17×105 2.93×104±1.26×104 2.00×104±1.34×104 7.01×103±1.17×103
HEK 293 2.16×106±9.73×103 3.96×104±6.44×103 5.80×104±1.95×104 9.07×103±3.28×103
U-87MG 4.04×106±4.11×105 1.08×104±1.19×103 1.32×105±9.17×103 N/D
*
The cells were infected with AAV-CMV-Luc vectors and luciferase activities were analyzed 48 hour later. AAV infectivity was expressed as 
mean Luciferase activity (RLU/mg protein) ±SEM.
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